In the BioHarmony Drug Report Database

"Preview" Icon

Cabazitaxel

Jevtana (cabazitaxel) is a small molecule pharmaceutical. Cabazitaxel was first approved as Jevtana on 2010-06-17. It is used to treat prostatic neoplasms in the USA. It has been approved in Europe to treat castration-resistant prostatic neoplasms and prostatic neoplasms. The pharmaceutical is active against tubulin beta chain. Jevtana’s patents are valid until 2030-10-27 (FDA).

 

Trade Name

 

Jevtana
 

Common Name

 

cabazitaxel
 

ChEMBL ID

 

CHEMBL1201748
 

Indication

 

castration-resistant prostatic neoplasms, prostatic neoplasms
 

Drug Class

 

Antineoplastics, taxane derivatives

Image (chem structure or protein)

Cabazitaxel structure rendering